Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2017 08:00 ET | Source: MyoKardia, Inc.

Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
November 13, 2017 19:15 ET | Source: MyoKardia, Inc.

MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
November 02, 2017 16:02 ET | Source: MyoKardia, Inc.

MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress

Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy MyoKardia to Initiate EXPLORER-HCM as Pivotal Trial in Second Quarter 2018 Company...
November 01, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
October 31, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
October 26, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
September 27, 2017 07:30 ET | Source: MyoKardia, Inc.

MyoKardia Provides Update on MYK-491 Clinical Progress

Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018 Next Trial of MYK-491 in DCM Patients...
September 18, 2017 12:45 ET | Source: MyoKardia, Inc.

MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision...
August 30, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
August 14, 2017 11:14 ET | Source: MyoKardia, Inc.

MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for...